Cargando…
Novel in-situ gel for intravesical administration of ketorolac
The urinary bladder stores urine until the time of urination. Systemic administration of drugs to treat bladder diseases faces several limitations. Therefore, intravesical drug delivery is a promising alternative route of administration. An in-situ gel is used to form a gel inside the bladder cavity...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128712/ https://www.ncbi.nlm.nih.gov/pubmed/30202226 http://dx.doi.org/10.1016/j.jsps.2018.03.014 |
_version_ | 1783353693930782720 |
---|---|
author | Sherif, Abdelrahman Y. Mahrous, Gamal Mohamed Alanazi, Fars Kaed |
author_facet | Sherif, Abdelrahman Y. Mahrous, Gamal Mohamed Alanazi, Fars Kaed |
author_sort | Sherif, Abdelrahman Y. |
collection | PubMed |
description | The urinary bladder stores urine until the time of urination. Systemic administration of drugs to treat bladder diseases faces several limitations. Therefore, intravesical drug delivery is a promising alternative route of administration. An in-situ gel is used to form a gel inside the bladder cavity and ensure continuous release of the drug even after urination. The objective of the present study was to optimize an in-situ gel formulation of poloxamer and chitosan for intravesical delivery of ketorolac tromethamine. The gelling temperature of the prepared combinations ranged from 20.67 to 25.8 °C. In-vitro release of KT was sustained for up to 7 h using a poloxamer concentration ranging from 17% to 19% and a chitosan concentration ranging from 1% to 2%. Design-Expert® 10 was used to select the optimized formulation (poloxamer/chitosan 17/1.589% w/w) which significantly (p < 0.05) extended the drug release more than each polymer alone. An ex-vivo study showed the ability of the optimized formulation to sustain drug release after emptying two times to mimic urination. Furthermore, the formed gel adhered to the bladder tissue throughout the time period of the experiment. Intravesical administration of the optimized formulation to rabbits via catheter showed no obstruction of urine flow and continuous release of the drug for 12 h. |
format | Online Article Text |
id | pubmed-6128712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-61287122018-09-10 Novel in-situ gel for intravesical administration of ketorolac Sherif, Abdelrahman Y. Mahrous, Gamal Mohamed Alanazi, Fars Kaed Saudi Pharm J Article The urinary bladder stores urine until the time of urination. Systemic administration of drugs to treat bladder diseases faces several limitations. Therefore, intravesical drug delivery is a promising alternative route of administration. An in-situ gel is used to form a gel inside the bladder cavity and ensure continuous release of the drug even after urination. The objective of the present study was to optimize an in-situ gel formulation of poloxamer and chitosan for intravesical delivery of ketorolac tromethamine. The gelling temperature of the prepared combinations ranged from 20.67 to 25.8 °C. In-vitro release of KT was sustained for up to 7 h using a poloxamer concentration ranging from 17% to 19% and a chitosan concentration ranging from 1% to 2%. Design-Expert® 10 was used to select the optimized formulation (poloxamer/chitosan 17/1.589% w/w) which significantly (p < 0.05) extended the drug release more than each polymer alone. An ex-vivo study showed the ability of the optimized formulation to sustain drug release after emptying two times to mimic urination. Furthermore, the formed gel adhered to the bladder tissue throughout the time period of the experiment. Intravesical administration of the optimized formulation to rabbits via catheter showed no obstruction of urine flow and continuous release of the drug for 12 h. Elsevier 2018-09 2018-03-27 /pmc/articles/PMC6128712/ /pubmed/30202226 http://dx.doi.org/10.1016/j.jsps.2018.03.014 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Sherif, Abdelrahman Y. Mahrous, Gamal Mohamed Alanazi, Fars Kaed Novel in-situ gel for intravesical administration of ketorolac |
title | Novel in-situ gel for intravesical administration of ketorolac |
title_full | Novel in-situ gel for intravesical administration of ketorolac |
title_fullStr | Novel in-situ gel for intravesical administration of ketorolac |
title_full_unstemmed | Novel in-situ gel for intravesical administration of ketorolac |
title_short | Novel in-situ gel for intravesical administration of ketorolac |
title_sort | novel in-situ gel for intravesical administration of ketorolac |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128712/ https://www.ncbi.nlm.nih.gov/pubmed/30202226 http://dx.doi.org/10.1016/j.jsps.2018.03.014 |
work_keys_str_mv | AT sherifabdelrahmany novelinsitugelforintravesicaladministrationofketorolac AT mahrousgamalmohamed novelinsitugelforintravesicaladministrationofketorolac AT alanazifarskaed novelinsitugelforintravesicaladministrationofketorolac |